TFS and survival states for immune checkpoint inhibitor plus tyrosine kinase inhibitor (TKI) combination are of interest.Methods:Overall, 651 patients (pts) with aRCC were randomized to receive 1L NIVO + cabozantinib (CABO) or SUN in the CheckMate 9ER trial; treatment continued until progression ...
The trial also includes several secondary safety and efficacy endpoints, including overall survival (OS). The study is ongoing to assess the second dual primary endpoint of PFS in patients receiving Opdivo plus Yervoy compared to Opdivo alone across all l...
Moreover, a final evaluation of HRQoL in relation to efficacy in CheckMate 274 should consider data for overall survival, which are not yet available. Limitations of the present study include assessment of HRQoL in <50% of patients from week 31 onward, largely because of patients discontinuing ...
Background Nivolumab (NIVO) + ipilimumab (IPI) combination demonstrated improved overall survival (OS) benefits vs chemotherapy as first-line treatment for advanced NSCLC in both tumor programmed death ligand 1 (PD-L1) expression ≥ 1% and < 1% in CheckMate 227. CheckMate 817 is a multi-cohort...
Phase 2 CheckMate 069 Study Suggests Nivolumab Plus Ipilimumab May Improve Overall Survival in MelanomaJonathan GoodmanMPhilOncology Editor